Spyre Therapeutics, Inc. SYRE
Super Investor & Insider
| Data filing | Data op. | Insider | Ruolo | Tipo | Prezzo | Quantità | Valore |
|---|---|---|---|---|---|---|---|
| 2026-06-03 | 2026-06-03 | Sloan Sheldon | Chief Medical Officer | Vendita | $75.00 | -8,333 | $624,975 |
| 2026-06-03 | 2026-06-01 | Turtle Cameron | Chief Executive Officer | Vendita | $69.40 | -3,557 | $246,856 |
| 2026-06-03 | 2026-06-01 | Turtle Cameron | Chief Executive Officer | Vendita | $70.50 | -8,149 | $574,505 |
| 2026-06-03 | 2026-06-01 | Turtle Cameron | Chief Executive Officer | Vendita | $71.38 | -3,294 | $235,126 |
| 2026-06-03 | 2026-06-01 | Burrows Scott L | Chief Financial Officer | Vendita | $69.75 | -1,801 | $125,620 |
| 2026-06-03 | 2026-06-01 | Burrows Scott L | Chief Financial Officer | Vendita | $70.77 | -2,599 | $183,931 |
| 2026-06-03 | 2026-06-01 | Burrows Scott L | Chief Financial Officer | Vendita | $72.06 | -3,100 | $223,386 |
| 2026-05-08 | 2026-05-08 | Henderson Michael Thomas | Dir | Vendita | $72.57 | -2,404 | $174,458 |
| 2026-05-08 | 2026-05-08 | Henderson Michael Thomas | Dir | Vendita | $73.72 | -33,513 | $2.5M |
| 2026-05-08 | 2026-05-08 | Henderson Michael Thomas | Dir | Vendita | $74.76 | -24,814 | $1.9M |
| 2026-05-08 | 2026-05-08 | Henderson Michael Thomas | Dir | Vendita | $75.35 | -19,269 | $1.5M |
| 2026-05-01 | 2026-05-01 | Burrows Scott L | Chief Financial Officer | Vendita | $71.37 | -12,500 | $892,125 |
| 2026-05-01 | 2026-05-01 | Sloan Sheldon | Chief Medical Officer | Vendita | $69.53 | -21,306 | $1.5M |
| 2026-05-01 | 2026-05-01 | Sloan Sheldon | Chief Medical Officer | Vendita | $70.61 | -19,656 | $1.4M |
| 2026-05-01 | 2026-05-01 | Sloan Sheldon | Chief Medical Officer | Vendita | $71.56 | -8,777 | $628,082 |
| 2026-05-01 | 2026-05-01 | Sloan Sheldon | Chief Medical Officer | Vendita | $72.94 | -12,777 | $931,954 |
| 2026-05-01 | 2026-05-01 | Sloan Sheldon | Chief Medical Officer | Vendita | $73.74 | -10,358 | $763,799 |
| 2026-05-01 | 2026-05-01 | Sloan Sheldon | Chief Medical Officer | Vendita | $74.60 | -5,059 | $377,401 |
| 2026-05-01 | 2026-05-01 | Sloan Sheldon | Chief Medical Officer | Vendita | $75.37 | -400 | $30,148 |
| 2026-05-01 | 2026-05-01 | Turtle Cameron | Chief Executive Officer | Vendita | $69.54 | -5,300 | $368,562 |
| 2026-05-01 | 2026-05-01 | Turtle Cameron | Chief Executive Officer | Vendita | $70.77 | -3,600 | $254,772 |
| 2026-05-01 | 2026-05-01 | Turtle Cameron | Chief Executive Officer | Vendita | $71.76 | -1,000 | $71,760 |
| 2026-05-01 | 2026-05-01 | Turtle Cameron | Chief Executive Officer | Vendita | $73.14 | -3,100 | $226,734 |
| 2026-05-01 | 2026-05-01 | Turtle Cameron | Chief Executive Officer | Vendita | $74.23 | -1,700 | $126,191 |
| 2026-05-01 | 2026-05-01 | Turtle Cameron | Chief Executive Officer | Vendita | $74.96 | -300 | $22,488 |
| 2026-04-03 | 2026-04-01 | Turtle Cameron | Chief Executive Officer | Vendita | $49.20 | -12,344 | $607,325 |
| 2026-04-03 | 2026-04-01 | Turtle Cameron | Chief Executive Officer | Vendita | $49.92 | -2,656 | $132,588 |
| 2026-04-03 | 2026-04-01 | Sloan Sheldon | Chief Medical Officer | Vendita | $50.00 | -7,958 | $397,900 |
| 2026-04-03 | 2026-04-01 | Burrows Scott L | Chief Financial Officer | Vendita | $49.21 | -6,200 | $305,102 |
| 2026-04-03 | 2026-04-01 | Burrows Scott L | Chief Financial Officer | Vendita | $49.98 | -1,300 | $64,974 |
| 2026-03-03 | 2026-03-03 | Burrows Scott L | Chief Financial Officer | Vendita | $40.56 | -2,300 | $93,288 |
| 2026-03-03 | 2026-03-03 | Burrows Scott L | Chief Financial Officer | Vendita | $41.66 | -200 | $8,332 |
| 2026-03-03 | 2026-03-02 | Turtle Cameron | Chief Executive Officer | Vendita | $41.73 | -5,900 | $246,207 |
| 2026-03-03 | 2026-03-02 | Turtle Cameron | Chief Executive Officer | Vendita | $42.49 | -9,100 | $386,659 |
| 2026-02-04 | 2026-02-02 | Turtle Cameron | Chief Executive Officer | Vendita | $31.82 | -957 | $30,452 |
| 2026-02-04 | 2026-02-02 | Turtle Cameron | Chief Executive Officer | Vendita | $32.87 | -14,043 | $461,593 |
| 2026-01-06 | 2026-01-02 | Turtle Cameron | Chief Executive Officer | Vendita | $30.47 | -12,709 | $387,243 |
| 2026-01-06 | 2026-01-02 | Turtle Cameron | Chief Executive Officer | Vendita | $31.79 | -2,191 | $69,652 |
| 2026-01-06 | 2026-01-02 | Turtle Cameron | Chief Executive Officer | Vendita | $32.39 | -100 | $3,239 |
| 2025-12-03 | 2025-12-01 | Turtle Cameron | Chief Executive Officer | Vendita | $28.73 | -10,995 | $315,886 |
| 2025-12-03 | 2025-12-01 | Turtle Cameron | Chief Executive Officer | Vendita | $29.83 | -4,005 | $119,469 |
| 2025-11-05 | 2025-11-03 | Turtle Cameron | Chief Executive Officer | Vendita | $23.13 | -28,155 | $651,225 |
| 2025-11-05 | 2025-11-03 | Turtle Cameron | Chief Executive Officer | Vendita | $23.66 | -16,845 | $398,553 |
| 2025-09-03 | 2025-09-02 | Burrows Scott L | Chief Financial Officer | Vendita | $16.26 | -18,428 | $299,639 |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation antibodies engineered for prolonged activity in the body, formulated for delivery as monotherapies or combination therapies. These innovative antibodies target validated mechanisms to address inflammatory bowel disease (IBD) s…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees112
TickerSYRE
Statistics
Market Cap$6.85B
Revenue (TTM)$0
Net Income-$155.2M
Net Margin—
EPS—
P/E1.68
P/S—
P/B12.37
EV/EBITDA-28.00
ROE-31.1%
Dividend Yield—
Price$86.83
Data: Twelve Data · Revenue = mcap / P/S